Welcome To Achilles Therapeutics

Achilles Therapeutics is a biopharmaceutical company developing personalised T cell therapies targeting neoantigens: protein markers unique to each individual that are present on the surface of a cancer cell and can be detected by the immune system. Our approach is based on the science of tumour evolution which allows us to identify neoantigens that arise early in the cancer’s development and are retained as each tumour grows. These ‘clonal’ neoantigens are present on all the cancer cells and are completely absent from a patient’s healthy tissue. By directing T cells therapies to clonal neoantigens we can for the first time target every cancer cell without attacking healthy tissue.

About Us+

Latest News

Achilles Therapeutics to Present at the Jefferies 2019 London Healthcare Conference

14/11/2019

Stevenage, UK 14 November 2019 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announced that Dr. Iraj…

Read More +

Achilles Therapeutics Appoints Beverley Carr as Chief Business Officer – Brings 20+ years of business development experience – Formerly VP, Business Development for the Immuno-inflammation Therapy Area at GSK

21/10/2019

Stevenage, UK 21 October 2019 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announces it has appointed…

Read More +

ACHILLES THERAPEUTICS RAISES £100 MILLION IN OVERSUBSCRIBED SERIES B FINANCING

03/09/2019

– Leading international syndicate led by RA Capital and cornerstoned by founding investor Syncona – Confirms depth of support for clonal…

Read More +

ACHILLES THERAPEUTICS RECEIVES CTA APPROVAL FOR PHASE I/II STUDY IN METASTIC OR RECURRENT MELANOMA – Second CTA approval in 2019 – the first was for a NSCLC study

13/02/2019

Stevenage, UK 13 February 2019 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announces the approval by…

Read More +

ACHILLES THERAPEUTICS APPOINTS DR MARKUS DANGL AS CHIEF SCIENTIFIC OFFICER

12/02/2019

Stevenage, UK 12 February 2019 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announces the appointment of…

Read More +

ACHILLES THERAPEUTICS RECEIVES CTA APPROVAL FOR PHASE I/II STUDY IN NON-SMALL CELL LUNG CANCER – Ground-breaking clinical trial in patients with significant unmet medical need to start this year

21/01/2019

Stevenage, UK 21 January 2019 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announces that its Clinical…

Read More +

ACHILLES THERAPEUTICS APPOINTS DR EDWIN MOSES AS CHAIRMAN OF ITS BOARD OF DIRECTORS AND DR IRAJ ALI AS CHIEF EXECUTIVE OFFICER

10/12/2018

Stevenage, UK; 10 December 2018 – Achilles Therapeutics (“Achilles” or “the Company”), a biopharmaceutical company using neoantigens to develop personalised cancer…

Read More +

ACHILLES TODAY ANNOUNCES THAT IT HAS APPOINTED SENIOR PHARMACEUTICAL EXECUTIVE MICHAEL F. GIORDANO, M.D., TO ITS BOARD OF DIRECTORS.

19/09/2018

Stevenage, 19 September 2018 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing novel cancer immunotherapies targeting clonal neoantigens, today announced that it…

Read More +

ACHILLES’ FOUNDERS MAP TRUNCAL AND BRANCHED MUTATIONS AND COPY NUMBER EVENTS TO PREDICT EARLY RELAPSE IN NON-SMALL CELL LUNG CANCER.

26/04/2017

Achilles Founders map truncal and branched mutations and copy number events to predict early relapse in non-small cell cancer lungs, opening…

Read More +

ACHILLES STARTS 2017 WITH MOVE TO STEVENAGE BIOSCIENCE CATALYST

03/01/2017

Achilles Therapeutics starts 2017 with move to Stevenage Bioscience Catalyst Immunotherapy company joins growing cell & gene therapy community on campusStevenage, UK,…

Read More +

The Science

Achilles was founded by world-leading experts in cancer evolution, bioinformatics and the development of cell-based immunotherapies. The company brings together these disciplines to develop next-generation, patient-specific cell therapies that harness the immune system to destroy cancer cells.

PROFESSOR CHARLIE SWANTON

Co-founder Charlie Swanton speaks about his career, the advent of immunotherapy and what the Achilles team are looking to achieve.